Serum Institute of India Pvt. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Serum Institute of India Pvt. Ltd.
A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.
While a Star Health study found high hospitalization costs for COVID-19 patients in India, those vaccinated paid 24% less and faced 81% lower mortality risk. However, insurers are unlikely to offer lower premiums to those vaccinated, even as the prospects for an overall hike remain uncertain, say experts.
Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population.
With fast-tracked development and deployment of COVID-19 vaccines yielding results, experts call for similar urgency and funding impetus to progress new vaccines for TB, which still claims 4,000 lives daily. Over 15 candidates have been in development for years, with hope now abounding around the potential of new platforms like mRNA to accelerate efforts.
- Large Molecule
- Other Names / Subsidiaries
- Bilthoven Biologicals